C-TX87TransportVehicle platform, biotherapeutics, barrier-crossing therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across varous dose levels of DNL952 in participants with late-onset Pompe disease (LOPD).
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity.
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months); followed by an open-label extension (OLE), which extends through Week 97 (approximately 18 months); and a long-term extension (LTE), which extends through Week 193 (Year 4). Participants with MPS IIIA will be enrolled in two planned cohorts, and additional participants with MPS IIIA may be enrolled in three optional cohorts.
This is a multiregional open-label extension (OLE) to assess the safety, tolerability, and efficacy of long-term treatment with tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant intravenous (IV) enzyme replacement therapy (ERT) for Hunter syndrome (MPS II). Participants who complete at least through the Week 49 visit in Study DNLI-E-0002 and do not discontinue study intervention early and participants who complete Study DNLI-E-0007 will be enrolled in this OLE. All participants will receive DNL310 for up to 5 years from the time of entry in this OLE. Participants, site staff, and the Sponsor will remain blinded to the original treatment assignment for participants entering this OLE from Study DNLI-E-0007.
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL919.
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28 days, followed by an 18-month open-label extension, designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL343 in participants with amyotrophic lateral sclerosis (ALS)
This is a Phase 1 relative bioavailability study carried out in approximately 24 healthy male subjects and healthy female subjects of non childbearing potential to investigate the effects of formulation and food on the safety, tolerability, and pharmacokinetics (PK) of DNL343.
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome). Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.
This is a Phase 1 study carried out at a single site in 88 healthy male subjects and healthy female subjects of non childbearing potential to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DNL343.
This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of disease in participants with MPS II who are aged ≤30 years at the time of enrollment.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), and 28-day safety study of orally administered DNL151 in healthy volunteers.
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study conducted in three parts.
Commuter Conference: Denali Therapeutics: Behind the Scenes of a 2026 Facility of the Year Awards (FOYA) Finalist - International Society of Pharmaceutical Engineers – San Francisco|ISPE-SF Skip to content About Board of Directors Contact Us Membership Member Application Member Directory Annual Sponsorships Events Gallery Get Involved Search Join Today Member Login Facebook icon Instagram icon LinkedIn icon YouTube Flckr Commuter Conference: Denali Therapeutics: Behind the Scenes of a 2026 Facility of the Year Awards (FOYA) Finalist Back to Search Commuter Conference: Denali Therapeutics: Behi … ancisco - a Facility which went on to win the ISPE Overall Facility of the Year Award in 2023. Leah holds a Master of Engineering in Professional Practice degree from University of Wisconsin, Madison and a Bachelor of Chemical Engineering degree from the University of Minnesota, Twin Cities. Abigail Jones, AIA, LEED AP BD+C, Project Architect at CRB Abigail has over 10 years of architectural experience, regularly leading complex projects and managing multidisciplinary t
DRS 1 filename1.htm Draft Registration Statement Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 8, 2017. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DENA … ; per share. We intend to apply to list our common stock on under the symbol “DNLI.” We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. Investing in our common s … nd impact on disease progression of our product candidates. We believe that the application of these principles will significantly increase the probability of success and will accelerate the timing to bring effective therapeutics to patients with neurodegenerative diseases. 2 Table of Contents Degenogenes Since 2007, the number of genetic associations discovered in neurodegenerative diseases has grown rapidly, with more than 100 genes associated with Alzheimer&# … erapeutic efficacy which will be evaluated in future patient trials. We plan to submit an IND or CTA for DNL151 in the fourth quarter of 2017. Our lead RIPK1 product candidate, DNL747, is a potent, selective and brain penetrant small molecule inhibitor of RIPK1 for Alzheimer’s disease and ALS. Microglia are the resident immune cells of the brain and play a significant role in neurodegeneration. RIPK1 activation in microglia results in production of a number of pro-inflam … mage. Pending the results from our IND-enabling preclinical studies, we plan to submit an IND or CTA for DNL747 in early 2018 and initiate a Phase 1 clinical trial in healthy volunteers in the first half of 2018. Our four other core programs all leverage our proprietary BBB platform technology to deliver antibody-based or enzyme-based therapies t
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Denali Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 12 May 2026 Denali Therapeutics, Inc. Public Company | 2013 | California, United States | 250-500 | NASDAQ: DNLI | www.denalitherapeutics.com Public Company | 2013 | California, United States | 250-500 | NASDAQ: DNLI | www.denalitherapeutics.com Last update 12 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Other Di … way for a global Phase 3 confirmatory study. Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for DNL126 for Sanfilippo syndrome type A in 2027. DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia (FTD-GRN) Denali is conducting a Phase 1/2 study of DNL593, an investigational, intravenously administered progranulin replacement therapy utilizing Denali’s Protein TransportVehicle™ (PTV) to deliver progranulin ac … S I; and DNL422 (OTV:SNCA) for Parkinson’s disease. Denali is on track to submit a regulatory filing for DNL921 in the first half of 2026 to begin clinical development of this TV-enabled anti-amyloid program for Alzheimer’s disease. Corporate Updates As previously announced in connection with the approval of AVLAYAH, the FDA granted Denali Therapeutics a Rare Pediatric Disease Priority Review Voucher (PRV). This voucher may be used to obtain priority review for a … PRV). This voucher may be used to obtain priority review for a future marketing application and can be transferred to another sponsor. On March 27, 2026 , Denali received $200 million in gross proceeds in connection with the closing of the transactions under a synthetic royalty funding agreement signed in December 2025 with Royalty Pharma Investments 2023 ICAV. On April 3, 2026 , Denali announced it received notification from Takeda of its decision to terminate the collaborat … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Does Denali Therapeutics Sponsor H1B & Green Card Visas? | Ellis Home Services Pricing About Resources Login Schedule a Call Services From employment-based visas to family petitions, adjustment of status, and everything in between—we handle all immigration matters. The options shown here are just some of our most common services. Get In Touch Visa Options H-1B $3,000 H-1B1 $3,000 TN $2,500 O-1 $12,000 L-1 $10,000 J-1 $2,500 E-1/E-2 $10,000 E-3 $3,000 Green Card Options EB-1A $12,000 EB-2 NIW $12,000 EB-2 PERM $12,000 EB-3 PERM $12,000 Other Naturalization $5,000 Resources Tools Visa Sponso … mate your H-1B lottery chances News DHS Proposes 75% Increase to US Citizenship Application Fee Supreme Court Ruling on Birthright Citizenship: What It Means for Families H-1B Visa Update: $100,000 Fee Temporarily Reinstated Following Court Stay Judge Strikes Down Trump's $100,000 H-1B Visa Fee — But Can It Return? Is USCIS Really Ending Adjustment of Status? An Immigration Attorney's Analysis of the May 2026 Memo See all news Articles Birthright Citizenship in the
Denali Therapeutics Inc - WKN A2H9G8, ISIN US24823R1059 | DivvyDiary Um DivvyDiary zu benutzen, benötigst du JavaScript. Hier findest du die Anleitung wie du JavaScript in deinem Browser einschaltest . DivvyDiary Dividend Calendar Features Pricing Blog All Securities My Portfolio EN Login Dividend Calendar Features Pricing Blog All Securities My Portfolio Unknown User You are not signed in Login Denali Therapeutics Inc United States €22.47 Quote Currency EUR USD CHF GBP CAD ── AED AFN ALL AMD ANG AOA ARS AUD AWG AZN BAM BBD BDT BGN BHD BIF BMD BND BOB BRL BSD BTC BTN BWP BYN BYR BZD CAD CDF CH … 332 - #.##% none UBS (Lux) Investment SICAV 2 - UBS (Lux) Digital Health Equity Fund P acc LU1683285164 A2H661 CR4X 2.26% 13,857 - #.##% none Edmond de Rothschild Fund - Healthcare N LU1160356850 A14URQ 1.25% 30,697 - #.##% none Access all 8 ETFs? Exclusive feature for our aristocrats. Upgrade Security Weight Become an aristocrat Popularity Become an aristocrat Div.% Div.CAGR 5Y Div.Freq. Frequently Asked Questions about Denali Therapeutics Inc How much dividend does Denali T
DENALI THERAPEUTICS H-1B Visa Sponsorship: 65 LCA Filings | layoffhedge layoff hedge Get Hired H-1B Join Us? Home › H-1B Explorer › DENALI THERAPEUTICS DENALI THERAPEUTICS H-1B Visa Sponsorship FY2015 to FY2026 · U.S. Department of Labor LCA disclosure data LCA Filings 65 National Rank #9311 of 9,347 Median Wage $130,598 States With Filings 2 DENALI THERAPEUTICS ranks #9311 of 9,347 employers tracked on the layoffhedge H-1B Explorer, with 65 LCA filings from FY2015 through FY2026. The median reported wage across its filings is $130,598. Its largest state footprint is Calif … 1B Explorer → Source and method. U.S. Department of Labor, Labor Condition Application (LCA) disclosure files, FY2015 through FY2026. Each certified LCA filing counts once, regardless of how many worker positions it covers. FY2026 includes Q1 only (October to December 2025). Median wage is the median of reported LCA wages for this employer. An LCA is a required first step of the H-1B process and does not by itself mean a visa was issued. Data free to cite with attributio
Grants & Sponsorships - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Pipeline Medical Professionals Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About
Patients - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Grants & Sponsorships Learn More We value the independence of non-profit organizations and aim to build relationships that are open, transparent and rooted in trust. We support charitable grants and sponsorships to 501(c)(3) organizations whose mission and purpose aligns with our therapeutic areas of focus. Learn More Early Access Program Early Access Program An early access program (EAP), also sometimes referred to as expanded access, is a mechani
Global Head of Medical Information (Remote Eligible) in South San Francisco at Denali Therapeutics Inc. | Apply now! – StudySmarter – Talents Everything for your career Find a job Global Head of Medical Information (Remote Eligible) in South San Francisco Apply Now Apply Now Job Board Companies Denali Therapeutics Inc. Global Head of Medical Information (Remote Eligible) Global Head of Medical Information (Remote Eligible) in South San Francisco South San Francisco Full-Time 72000 - 108000 $ / year (est.) No home office possible Apply Now Apply Now D At a Glance Tasks: Lead medical inquiry man … haring your experiences on platforms like ResearchGate to enhance visibility. ✨ Apply Directly On Company Websites When you find a company you're excited about, like Denali Therapeutics Inc., go directly to their careers page and apply. Many biotech firms prefer to source candidates from their own sites. Also, it shows initiative and that you’re serious about joining the team! We think you need these skills to ace Global Head of Medical Information (Remote Eligible) in So … roduct Launch Experience Fast-Paced Environment Adaptability Some tips for your application 🫡 Showcase Your Scientific Skills: When applying for a full-time role in biotechnology, it's crucial to highlight your relevant scientific skills and experience. Include specific techniques or technologies you've worked with, like CRISPR or mass spectrometry, in your CV. This way, we can see that you have the hands-on experience necessary for the position at Denali Therapeutic … ring cross-functional team initiatives. This can make a huge difference in your application quality. How to prepare for a job interview at Denali Therapeutics Inc. ✨ Showcase Your Technical Know-How In biotechnology, it's crucial to demonstrate a strong grasp of relevant techniques and tools—so be prepared to discuss the lab methods you've used or any specific projects you’ve been part of. Bring along any data or results that highlight your contributions; we want to s … y data or results that highlight your contributions; we want to see how you can apply science to real-world problems! ✨ Brush Up on Your Problem-Solving Skills Biotech interviews often include hypothetical scenarios where you might have to troubleshoot a research problem. Practice articulating your thought process as you navigate these challenges
EX-99.1 2 ex991pressreleaseq42023.htm EX-99.1 Document Exhibit 99.1 Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – February 27, 2024 –  Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provid … on and stock-based compensation expenses, driven by higher headcount and equity award grants. Additionally, there was an increase in facility and other corporate costs for the year ended December 31, 2023 associated with the new Salt Lake City manufacturing facility. Cash, cash equivalents, and marketable securities were approximately $1.03 billion as of December 31, 2023. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad por
Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases Skip to content About Our Company Leadership Corporate Responsibility Corporate Sustainability Sustainability Approach Access to Medicines Sustainability Disclosures Ethics & Disclosures Ethics Transparency Disclosures Positions Corporate Giving Corporate Governance Governance Strategy Governance Structure Charters and Reports Science Areas of Focus Research and Development Pipeline Products Our Products Manufacturing Suppliers Clinical Trials Our Stories Newsroom Press Releases
Altos Labs About About Science Careers Careers Featured Contact About / Board of Directors Robert Nelsen Director Director " Altos is driven by the kind of science whose potential impact keeps you up at night thinking. Combined with a biotech “dream team” to find medicines in the science. ARCH is privileged to back Rick, Hal, and Hans with our largest commitment ever. " Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150
Takeda Breaks Up With Denali, Dumps Dementia Drug - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All Ne … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Takeda Breaks Up With Denali, Dumps Dementia Drug April 6, 2026 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, Mininyx Doodle Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Al … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Collaboration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Collaboration IN PARTNERSHIP WITH INTELLIA THERAPEUTICS The commercial launch playbook: Team structure, readiness and execution Intellia Therapeutics’s Senior Vice President Maria Natale discusses why the most successful launches are shaped long before approval, with strategy, structure and patient insight at the core. June 15, 2026 … · 3 min read Press Releases MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D June 23, 2026 · 10 min read Press Releases NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital June 23, 2026 · 1 min read Load More BioSpace is the digital hub for life science news and jobs. We prov … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Flagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader Award - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Flagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader Award November 15, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Flagship Pioneering today announced the recipient of the firm’s annual Pioneering Leader Award. CAMBRIDGE, Mass. , … Pioneering today announced the recipient of the firm's annual Pioneering Leader Award. The 2018 award recognized Ryan Watts , Ph.D., CEO of Denali Therapeutics, a company dedicated to defeating neurodegenerative diseases. Denali has grown rapidly under Dr. Watts' leadership and made its initial public offering in December 2017 . Dr. Watts accepted the award at Flagship's 2018 Annual Meeting, held this week in Cambridge, Massachusetts . Denali was created in 2015 by Drs. Marc … lop drugs." Previous recipients of Flagship's annual entrepreneurial leadership award include Stéphane Bancel of Moderna (2014), Faheem Hasnain of Receptos (2015), David Schenkein of Agios (2016), and David Perry of Indigo Agriculture (2017). Learn more about Denali Therapeutics at www.denalitherapeutics.com About Flagship Pioneering Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustaina … yan-watts-ceo-of-denali-therapeutics-as-recipient-of-the-2018-pioneering-leader-award-300751135.html SOURCE Flagship Pioneering Twitter LinkedIn Facebook Email Print Events LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · 4 min read
Pfizer Board Member Jumps Ship to $217 Million Startup Denali - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Pfizer Board Member Jumps Ship to $217 Million Startup Denali May 21, 2015 | 3 min read Twitter LinkedIn Facebook Email Print Lukas Roth May 21, 2015 By Riley McDermid and Mark Terry , BioSpace.com Breaking News Staff Brand new biotech San Francisco startup Denali Therapeutics has claimed ano … sciences , ARCH Venture Partners , Flagship Ventures , and the Alaska Permanent Fund , represented by Crestline . “The best scientists in the world are now calling us,” said Robert Nelsen , co-founder of ARCH Ventures in a statement. “You can’t wait 10 or 20 years for the perfect study in Alzheimer’s when it’s going to cost us a trillion dollars in today’s dollars by 2050. The societal cost of these diseases is mind-blowing.” This year marks significant research and industry … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Secarna Pharmaceuticals and Denali Therapeutics Enter Into Research and Option Agreement to Develop Novel Antisense Therapies in the Field of Neurodegenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Secarna Pharmaceuticals and Denali Therapeutics Enter Into Research and Option Agreement to Develop Novel Antisense Therapies in the Field of Neurodegenerative Diseases October 13, 2020 | 4 min read Twitter LinkedIn Facebook Email Print Secarna Pharmaceuticals GmbH today announced that the Co … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
What You Need to Know About Denali - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business What You Need to Know About Denali January 3, 2017 | 4 min read Twitter LinkedIn Facebook Email Print January 9, 2017 By Mark Terry , BioSpace.com Breaking News Staff Denali Therapeutics was launched in May 2015 by three former Genentech researchers— Ryan Watts , former director of Genentech … sciences , ARCH Venture Partners , Flagship Ventures , and the Alaska Permanent Fund , represented by Crestline . Other investors include sovereign wealth funds, public mutual funds and private family offices. On August 25, 2016, the company announced a $130 million Series B equity financing. All of its founding investors participated in this round, which was led by Baillie Gifford , a UK-based mutual fund and included several new and large institutional investors, who were n … t identified. Pipeline Denali also announced in August its first Clinical Trial Application (CTA) to initiate a Phase I trial. It has selected four specific pathways that are believed to be triggers or effectors of neurodegeneration. Those include degenogenes, defective intracellular trafficking, glial dysfunction, and axon degeneration. The CTA in Europe is for a small molecule RIP1 inhibitor with central nervous system (CNS) penetrant properties. RIP1 is a kinase that regul … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Publications - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Home Pipeline Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadership Investo
Denali Therapeutics Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcast … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Denali Therapeutics Inc. NEWS JOBS IN THE PRESS NEWS Parkinson’s disease Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints. May 22, 2026 · … ly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking over cell therapy-focused Neurona Therapeutics ; President Trump signed a new executive order supporting the development of psychedelic therapies, sparking fanfare and concern alike; and the FDA’s recent Replimune decision has triggered broader debate about the agency’s flexibility. April … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Denali Therapeutics: defeating…–Invest in Progress – Apple Podcasts Search Home New Top Charts Search 15 February 2023 42 min Denali Therapeutics: defeating degenerative diseases Invest in Progress Play We speak to Denali Therapeutics about overcoming the challenge of the blood-brain barrier to treat devastating neurodegenerative diseases. In this episode, Denali’s founder Ryan Watts tells Scottish Mortgage’s manager Tom Slater why he thinks his company can succeed where big pharma has failed to develop effective treatments for neurological disorders. The two discuss why the biotech company is … Audio production agency: Listen Producer: Phil Sansom Executive producer: Suzy Grant Production manager: Niamh Kidd Editorial lead: Malcolm Borthwick Hosted on Acast. See acast.com/privacy for more information. Episode Webpage Information Show Invest in Progress Frequency Updated fortnightly Published 15 February 2023 at 07:00 UTC Length 42 min Season 1 Episode 3 Rating Clean United Kingdom Select a country or region Africa, Middle East, and India See All Algeria Angola Arme
Woman of the Week: Denali Therapeutics’ Cindy Dunkle | PharmaVoice Skip to main content CONTINUE TO SITE ➞ Don't miss the most important voices in pharma Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | BioPharma Dive Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercial … he accolades. But what is really meaningful to me and where I get my reward and award comes from getting to serve and support people and leveraging their gifts and talents that will ultimately help us to achieve our goal. I don’t at all take for granted the opportunity I’ve been given to have an impact and the responsibilities that I have been given. And I certainly intend to stretch to make good on those who have invested in me. Taren: That’s very nice. And again, I knew you
ICYMI: BioHive's new podcast, HiveCast had it's first episode release on Wednesday! It took nearly 20 years of work for Denali Therapeutics to receive approval for their first drug. Ryan Watts… | BioHive Utah LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices a
Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches April 22, 2026 | 7 min read | Annalee Armstrong Twitter LinkedIn Facebook Email Print Denali Therapeutic CEO Ryan Watts accepts the Visionary of the Year award at BioHive Live in Salt Lake City, Uta … test professional moment of my life,” Watts said on Thursday, as he accepted an award from Utah’s biotech community hub, BioHive. Denali Therapeutics CEO Ryan Watts addresses the crowd at BioHive Live in Salt Lake City, Utah, on April 16, with members of the Denali staff behind him. / Dani @ LakeCity Photos, Courtesy BioHive Water under the bridge Watts told the same story to BioSpace on the sidelines of BioHive Live in Salt Lake City last week, reflecting on the accomplishme … how to handle therapies with clinical trials that were not straightforward. The application was based on a Phase 1/2 study of 47 patients—a single-arm study, like the kind that has drawn the FDA’s scrutiny for many companies over the past year. Denali in February 2025 reported a normalization of key biomarkers associated with Hunter syndrome, plus long-term safety data showing that the drug was well tolerated over two years. FDA Rare Disease Leaders Call for Regulatory Consis … · 8 min read · Heather McKenzie Read more The application was accepted without incident, granted priority review and set for a decision on January 5. In the meantime, Denali began staffing up the launch team, readying to have product available to deliver to patients as early as the end of 2025. Then, the other sh
Ep131: Ryan Watts on Neuroscie... - The Long Run with Luke Timmerman - Apple Podcasts بحث الرئيسية جديد قوائم الأفضل بحث ١٤ مارس ٢٠٢٣ ١ س ٦ د Ep131: Ryan Watts on Neuroscience Drug R&D The Long Run with Luke Timmerman تشغيل Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development. صفحة الويب الخاصة بالحلقة المعلومات البرنامج The Long Run with Luke Timmerman معدل البث مرتان في الشهر تاريخ النشر ١٤ مارس ٢٠٢٣ في ١٠:١٣ م UTC مدة الحلقة ١ س ٦ د التقييم ملائم الولايات المتحدة Español (México) Русский 简体中文 Français (France) 한국어 Português (Br
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Running Up That Hill: An Interview with Carole Ho, Denali Therapeutics genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsletters … tific understanding of disease, so she opted to become a neurologist. She did a residency at Mass General Hospital and a postdoc in basic research with Marc Tessier-Lavigne, PhD, to learn more about neuroscientific disorders amenable to novel therapies. Carole Ho, MD Denali Therapeutics After six years as an academic and an attending neurologist at Stanford, Ho moved to industry, where she has spent almost two decades. At Genentech, she headed the early clinical development g
Stanford University - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Scien … r's #Stanford University AI-powered ‘co-scientist’ wins prestigious Alzheimer’s prize Developers of an AI-powered ‘co-scientist’ have been awarded the $1 million Alzheimer’s Insights AI Prize. Mount Sinai scientists, led by Dr Kuan-lin Huang, won the prize for developing Biomni-AD, an advanced AI-powered ‘co-scientist’ designed to dramatically reduce the time required to generate scientific insights from complex biomedical data. Biomni-AD… Read More 2 April 2026 #News … using click chemistry A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More 27 July 2023 #Cancer Research #News #Trending News #Academic #Data management #Neuroscience #Stanford University Stanford president quits follow
Three Former Genentech Researchers Launch Neuroscience Company Denali Therapeutics With $217 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Three Former Genentech Researchers Launch Neuroscience Company Denali Therapeutics With $217 Million May 14, 2015 | 3 min read Twitter LinkedIn Facebook Email Print Lukas Roth May 14, 2015 By Mark Terry , BioSpace.com Breaking News Staff A new biotech company was launched today in San Francis … sciences , ARCH Venture Partners , Flagship Ventures , and the Alaska Permanent Fund , represented by Crestline . “The best scientists in the world are now calling us,” said Robert Nelsen , co-founder of ARCH Ventures in a statement. “You can’t wait 10 or 20 years for the perfect study in Alzheimer’s when it’s going to cost us a trillion dollars in today’s dollars by 2050. The societal cost of these diseases is mind-blowing.” This year marks significant research and industry … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Stanford investigating president over alleged research misconduct Skip to Main Content Eli Lilly Donald Trump Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Hospita …  protected] @DrewQJoseph Tags research scientific misconduct scientists To submit a correction request, please visit our Contact Us page . Trending A sweeping new AI to detect heart conditions is… A sweeping new AI to detect heart conditions is coming to OpenEvidence 6 surprising facts about sugar-laden, virus-fighting breast milk 6 surprising facts about sugar-laden, virus-fighting breast milk Embryo editing advances reignite ethical debates Embryo editing advanc
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases January 8, 2025 | 1 min read | Annalee Armstrong Twitter LinkedIn Facebook Email Print iStock, Anton Vierietin Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Agenda: Drug Discovery Day 2026 Toggle navigation Agenda Agenda Choose your pass AGENDA HH - 6:00 PM - 8:00 PM ET ROW 34, CAMBRIDGE, MA Hybrid Virtual 11:00 AM - 11:25 AM ET Beyond CRISPR CRISPR supercharged gene editing. But after a decade of focus on that breakthrough, some scientists are back at the drawing board — and the race is on for the next big gene editing tool. What strategies are leading the pack and what role will CRISPR play as new tools emerge? Hear from experts at the cutting edge of the newest technologies. sponsored by Laura Sepp-Lorenzino Principal GNMmeds LLC Albert Seymour
Robert Nelsen | Red Cell Partners Skip to content We're Hiring. Apply Now Red Cell Partners [Menu] [Close] Home Our Firm About Us Our People Newsroom Events Portfolio Our Practice Areas Healthcare Cyber National Security Our Companies Careers Work at Red Cell Open Positions Blog Subscribe to our Mailing List Robert Nelsen Senior Advisor, Healthcare Robert Nelsen is a Senior Advisor to Red Cell’s Healthcare Practice. He is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing a
Product & Pipeline - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Science Patients Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leade
Privacy Policy - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Privacy Policy Last Updated: September 28, 2025 At Denali Therapeutics Inc. (“Denali,” “our,” “we,” or “us”), we respect your privacy and appreciate the trust you have placed in us. This Privacy Policy (“Policy”) explains how Denali collects, uses, and shares Personal Information of visitors to our websites and online services, individuals who engage with us offline (such as through Denali products and product related services, conferences, resea … ors, and business partners (collectively, the “Services”). This Policy does not apply to Denali employees or to third-party websites or services. It is incorporated by reference into Denali’s Terms of Use (the “Terms”). By using our Services, you acknowledge that your Personal Information will be processed as described in this Policy. For individuals located within the European Union (“EU”), European Economic Area (“EEA”), United Kingdom (“UK”) or Switzerland, please refer to … ess employment inquiries including to: (i) send you a confirmation email if you submit an inquiry or application; (ii) contact you if we need more information related to your employment application, account profile or employment search; (iii) process your employment application; (iv) respond to your questions; and (v) contact you about employment positions that may be of interest to you (including through our employees or third-party recruiters contracted on our behalf) Marke … to regulatory authorities or sharing information with our business partners. To submit an Adverse Event Report, please visit this form. Compliance with applicable law and our own obligations. We may also process the information we collect about you or from you for the following purposes: (i) to enforce our Terms or other legal rights, including intellectual property infringement; (ii) as may be required by applicable laws and regulations or requested by any judicial process o … ation. If using an authorized agent to make a request on your behalf, they must submit proof of authorization from you. Please note that some of the rights above are not absolute rights and we may be unable to comply with a request due to certain exemptions or limitations under applicable laws. We will attempt to fulfill the requests to the exten
Ryan Watts | VIB Conferences Skip to main content Asset 2 Conferences User account menu Log in Main navigation Home Event archive Speakers archive About News archive Support us FAQ 0 0 items CHECKOUT Apply Breadcrumb Home > Ryan Watts Ryan Watts Denali Therapeutics, US More information Visit Ryan Watts' page Biography Ryan J. Watts, PhD is the President and Chief Executive Officer of Denali Therapeutics, a company founded to discover and develop medicines for neurodegenerative diseases. He is a co-founder and a member of the Board of Directors. Dr. Watts previously served as Director of t
Science - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Partnerships & Collaborations Contact Us Collaborations are core to Denali’s strategy to develop and commercialize our portfolio. We partner with leading biopharmaceutical companies, academic institutions, foundations and enabling technology companies to advance treatments for neurodegenerative diseases, lysosomal storage disorders and other serious diseases. Contact Us Product & Pipeline Patients Your browser does not support the video tag. Sci
dnli-20250417 0001714899 DEF 14A false iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares 0001714899 2024-01-01 2024-12-31 0001714899 2023-01-01 2023-12-31 0001714899 2022-01-01 2022-12-31 0001714899 2021-01-01 2021-12-31 0001714899 2020-01-01 2020-12-31 0001714899 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001714899 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:PeoMember 2024-01-01 2024-12-31 0001714899 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2023-01-01 2023-12-31 0001714899 ecd:EqtyAwrdsAdjsExclgValRprtdIn … strant as Specified In Its Charter) Payment of Filing Fee (Check all boxes that apply): x No fee required ¨ Fee paid previously with preliminary materials ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11   Table of Contents DENALI THERAPEUTICS INC. Dear Stockholder: I am pleased to invite you to attend the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Denali Therapeutics Inc. (R … www.virtualshareholdermeeting.com/DNLI2025, where you will be able to vote and submit questions electronically during the Annual Meeting. The attached Notice of Annual Meeting of Stockholders and proxy statement contain details of the business to be conducted at the Annual Meeting. Whether or not you attend the virtual Annual Meeting, it is important that your shares be represented and voted at the meeting. Therefore, I urge you to promptly vote and submit your proxy via the … ether or not you plan to attend the virtual Annual Meeting, we encourage you to submit your vote via the Internet, telephone or mail as soon as possible to ensure your shares are represented. For additional instructions for each of these voting options, please refer to the proxy card. Returning the proxy does not deprive you of your right to attend the Annual Meeting and to vote your shares at the Annual Meeting. Our proxy statement contains further information regarding voti … NSWERS ABOUT THE ANNUAL MEETING 1 BOARD OF DIRECTORS AND CORPORATE GOVERNANCE 9 PROPOSAL NO. 1 ELECTION OF DIRECTORS 24 PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 25 PROPOSAL NO. 3 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION 27 COMMITTEE REPORTS 28 EXECUTIVE OFFICERS 30 EXECUTIVE COMPENSATION 3
Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Your browser does not support the video tag. Transforming Life Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. We discover, develop and deliver medicines for people living with serious diseases. Science Crossing Biological Barriers We invented the TransportVehicle™ (TV) platform to enable a new class of barrier-crossing therapeutics with the potential to transform treatment for people living with serious diseases th
Momentum in Alzheimer's Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer's Disease Conference Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News … table moderated by Philip Scheltens , MD, PhD, Partner and Head of the Dementia Fund at EQT Life Sciences, featuring leading experts and investors in the Alzheimer's space, including the Dementia Discovery Fund, Alzheimer's Research UK, and Denali Therapeutics. The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer's therapeutics. CTAD will feature sessions an … Panelists: Howard Fillit , MD (ADDF), John Behr , PhD (Dementia Discovery Fund), Susan Kohlhaas , PhD (Alzheimer's Research UK), and Joe Lewcock , PhD (Denali Therapeutics) Additional sessions from ADDF-funded investigators will include: Keynote: "Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies" with Dr. Jeffrey Cummings on Wednesday, October 25 th at 4:20pm ET Late Breaker: " PrecivityAD2 blood test: An analytically and clinically … erosity of its donors, the ADDF has awarded more than $300 million to fund over 730 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/ . SOURCE Alzheimer's Drug Discovery Foundation 21 % more press release views with Request a Demo × Modal title Also from this source New Alzheimer's & Dementia Paper Highlights SpeechDx's Role in Advancing AI-Driven Too … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
Momentum in Alzheimer’s Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer’s Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer’s Disease | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy F … tegy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Conferences News Announcements Alzheimer's Matters Blog ADDF in the News Ways To Give Corporate Partners Planned Giving Matching Gifts Announcements Momentum in Alzheimer’s Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer’s Drug Discovery Foundation at 2023 Cl … dtable moderated by Philip Scheltens, MD, PhD, Partner and Head of the Dementia Fund at EQT Life Sciences, featuring leading experts and investors in the Alzheimer’s space, including the Dementia Discovery Fund, Alzheimer’s Research UK, and Denali Therapeutics. The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer’s therapeutics. CTAD … iences) Panelists: Howard Fillit, MD (ADDF), John Behr, PhD (Dementia Discovery Fund), Susan Kohlhaas, PhD (Alzheimer’s Research UK), and Joe Lewcock, PhD (Denali Therapeutics) Additional sessions from ADDF-funded investigators will include: Keynote: “Alzheimer’s Disease: The Drug Development Pipeline and Emerging Therapies” with Dr. Jeffrey Cummings on Wednesday, October 25 th at 4:20pm ET Late Breaker: “PrecivityAD2 blood test: An analytically … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention
Largest And Global Sovereign Wealth Fund Institute | SWFI SWF Summit Events Demo Login Services Subscription Membership Datafeeds/API Public Fund Monitor Advertising Consulting Quarterly News Policy Deals Europe Asia Real Estate Alternatives Real Assets Public Pension Private Equity Energy Crypto Infrastructure Fund Rankings SWF Public Pension Bank Endowment Central Bank Superannuation Foundation Manager Rankings Asset Manager Bank Financial Holding Company Crypto Wealth Manager Hedge Fund Manager Profiles SWF Public Pension Superannuation Endowment Central Bank State Owned Manager Family Offi … ice Afore Transactions Listed Equity Unlisted Equity Real Estate Private Equity Fund Real Estate Fund Credit Fund Infrastructure Active Equities RFPs Active Equities Active Fixed Income Private Equity Fund Real Estate Fund Credit Fund Real Estate Hedge Fund Consultant Events Demo Login Book a Demo Public Fund Monitor Pages Services Subscription Membership Datafeeds/API Public Fund Monitor Advertising Consulting Quarterly Fund Rankings Fund Manager Rankings Events News Researc … any Cannabis Company Central Bank Company Corporate Pension Credit Union Crypto Fund Manager Development Bank Endowment Export Credit Agency Family Enterprise Family Office Family Trust Finance Ministry Financial Holding Company Foundation Fund Government Government Bank Government Fund Healthcare Foundation Hedge Fund Manager Holding Company Insurance Investment Consultant Investment Trust Investor Joint Venture Land Bank Law Firm Media Company National Oil Company Native Am … t Venture Land Bank Law Firm Media Company National Oil Company Native American Fund Nonbank Lender Pension People Pharmaceutical Company Public Pension Real Estate Company Real Estate Investment Trust Retailer Safety Pension Sovereign Wealth Fund Special Purpose Entity State Owned Enterprise Superannuation Supranational Entity Trading Company Venture Capital Firm Wealth Manager Transactions All Transactions Active Equities Active Fixed Income Business Development Company Con … Active Fixed Income Business Development Company Consultant Convertible Credit Fund Cryptocurarencies Derivative ESG Fund Fixed Income Fund Hedge Fund Infrastructure Infrastructure Fund Insurance Listed Equity Multi-Asset Passive Equities Passive Fixed Income Private Equity Fund Real Asset Fund Real Estate Real Estate Fund Service Provider Smart
Denali Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Denali Therapeutics Website: Denali Therapeutics Business Area(s) Neurobiology Description Denali Therapeutics is headquartered in San Francisco, California, where its corporate operations and strategic initiatives are based. In addition to the San Francisco location, Denali has expanded it
The Escalator: Genentech, Denali Therapeutics, Eli Lilly and more HAYMARKET MARKETING COMMUNICATIONS: Campaign US MM+M PRWeek Newsletters | Log In | Register Search for: News Agencies Five Things to Know Data/Analytics Campaigns Pharma Podcasts Policy Media Technology People Moves Rare Disease In-Depth MM+M Best Places to Work 2025 Career and Salary Survey 2025 Healthcare Marketers Trend Report 2025 MM+M/Publicis Health Innovation Survey 2025 Events MM+M Awards MM+M Media Summit AI Deciphered Pinnacle Awards MM+M 40 Under 40 2025 MM+M Transform MM+M Health Marketing Influencer 25 Women of Dist
Denali Therapeutics Inc. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
Denali Therapeutics | pharmaphorum Skip to main content Sunday 28 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Development Market Access Oncology Arti
EX-10.16 3 d463296dex1016.htm EX-10.16 EX-10.16 Exhibit 10.16 CONFIDENTIAL Execution Version SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]. OPTION AND COLLABORATION AGREEMENT between DENALI THERAPEUTICS INC . and TAKEDA PHARMACEUTICAL COMPANY LIMITED TABLE OF CONTENTS Page Article 1 DEFINITION … defined herein) to Designated Targets (as defined herein) and Denali wishes to grant to Takeda an exclusive option to obtain a license under Denali’s intellectual property with respect to such Biologics Directed to such Designated Targets, and Takeda wishes to obtain such option, for purposes of developing, manufacturing and commercializing Optioned Products (as defined herein) in the Territory, in each case in accordance with the terms and conditions set forth below; a … ; the holders of capital stock of such Party approve a plan or proposal for the liquidation or dissolution of such Party. For the purpose of this definition of Change in Control, (a) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term “group” includes any group acting for the purpose of acquiring, holding or disposing of … uant to a Development Plan, Commercialization Plan or an Additional Development Proposal. 1.27 “ CNS Field ” means [***]. 1.28 “ Co-Commercialization Plan ” means, for each applicable Collaboration Program, a detailed plan and detailed budget for the Commercialization in the Field in the United States and/or China, as applicable, of Optioned Products included in such Collaboration Program for which the Non-Co … es. 1.35 “ Commercialization Budget ” means a rolling [***] Calendar Year budget setting forth the budgeted amounts estimated to be incurred in performance of the related Commercialization Plan in the first Calendar Year (or part thereof) of such budget and the overall estimated budget to be incurred in performan
%PDF-1.6 %���� 114 0 obj > endobj xref 114 25 0000000016 00000 n 0000001156 00000 n 0000001269 00000 n 0000001496 00000 n 0000001944 00000 n 0000002490 00000 n 0000002745 00000 n 0000002994 00000 n 0000005082 00000 n 0000005258 00000 n 0000005509 00000 n 0000005642 00000 n 0000034586 00000 n 0000075823 00000 n 0000100310 00000 n 0000100380 00000 n 0000100464 00000 n 0000104288 00000 n 0000104550 00000 n 0000104714 00000 n 0000104741 00000 n 0000105041 00000 n 0000105541 00000 n 0000106137 00000 n 0000000796 00000 n trailer ]/Prev 202117>> startxref 0 %%EOF 138 0 obj >stream h�b```b``�e`e`�bd … :def8bb45-beee-11b2-0a00-69983c647348 uuid:def8e2dd-beee-11b2-0a00-e3a9e27946e1 application/pdf Harpreet Ram (Contractor) Adobe PDF Library 25.1.201 0x01010012AEFFE7F8555E4BADE9F0C5EED70ADF D:20260218213124 endstream endobj 113 0 obj > endobj xref 0 114 0000000000 65535 f 0000106433 00000 n 0000106652 00000 n 0000110222 00000 n 0000110516 00000 n 0000110735 00000 n 0000115809 00000 n 0000116039 00000 n 0000124391 00000 n 0000144986 00000 n 0000145245 00000 n 0000145625 00000
%PDF-1.7 %���� 1 0 obj >/Metadata 303 0 R/ViewerPreferences 304 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 22 0 R 23 0 R 24 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=is ���U��0�\�)s8�L����֫XQ$�R�����x�%�R�� � 03��%���U�v�>�����w����r�������f� z��� � U�ŀ�_��|v� Kf�냿~�?~���dUZ �����ր��s��M�F���Y�h��g ��1�Bfx�;x~|�kz:�������N£�s�/�[։~�g�.����_�{?�y �AMʲQ;��+� ��e3*M�q�T�M�=�ZOg�����r3�>����P�* ������!˪��Sٕ��#��Ę��G�|Ҟ� ��:��ۨ�t��6����iV�8���r�
Plenary Speakers | AAIC | Alzheimer's Association Alzheimer’s Association International Conference | July 12-15, 2026 | London, United Kingdom, and Online ABOUT About AAIC Learn about the world's largest forum for the dementia research community. --> AAIC Scientific Program Committee Awards The Student Experience The ISTAART Experience Traveling to London Attendee Mobile App --> Conference Policies Contact Us Future Scientific Meetings Future Scientific Meetings Visa Invitation Letter --> ABSTRACTS Abstract Submission Overview Abstract and Session Submission Guidelines Developing Topics Submis … quest for Press Credentials REGISTER LOG IN TO AAIC REGISTRATION LOG IN TO AAIC SUBMIT AN ABSTRACT --> Plenary Speakers The Alzheimer's Association is pleased to welcome these distinguished plenary speakers to AAIC 2026. Sunday, July 12 Ryan Watts, Ph.D. CEO — Denali Therapeutics, United States Plenary session title: Accelerating the Discovery and Development of Medicines for Neurodegeneration Monday, July 13 Suzanne E. Schindler, M.D., Ph.D. Associate Professor, School of Me
Invest in Cigna, Northern Trust, VTv Therapeutics, Republic Services, and 570535AT1 for growth | Macroaxis LLC posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicki … nancing. The funds will support the company through an investigational new drug application and then into the clinic. #lifesciences #emergingcompanies Learn more: https://lnkd.in/eU8k943M 14 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in NOTRELOAD AI 222 followers 6mo Report this post Denali Therapeutics is selling about 9.1M shares at $17.50 and 2.3M pre-funded warrants at $17.49, raising roughly $200M before fees. Underwriters can bu
Senior Director, Medical Information (Remote Eligible) in South San Francisco at Denali Therapeutics Inc. | Apply now! – StudySmarter – Talents Everything for your career Find a job Senior Director, Medical Information (Remote Eligible) in South San Francisco Apply Now Apply Now Job Board Companies Denali Therapeutics Inc. Senior Director, Medical Information (Remote Eligible) Senior Director, Medical Information (Remote Eligible) in South San Francisco South San Francisco Full-Time No home office possible Apply Now Apply Now D At a Glance Tasks: Lead medical information initiatives and ensure … haring your experiences on platforms like ResearchGate to enhance visibility. ✨ Apply Directly On Company Websites When you find a company you're excited about, like Denali Therapeutics Inc., go directly to their careers page and apply. Many biotech firms prefer to source candidates from their own sites. Also, it shows initiative and that you’re serious about joining the team! We think you need these skills to ace Senior Director, Medical Information (Remote Eligible) in … Center Operations Management Adaptability Budget Management Some tips for your application 🫡 Showcase Your Scientific Skills: When applying for a full-time role in biotechnology, it's crucial to highlight your relevant scientific skills and experience. Include specific techniques or technologies you've worked with, like CRISPR or mass spectrometry, in your CV. This way, we can see that you have the hands-on experience necessary for the position at Denali Therapeutic … ring cross-functional team initiatives. This can make a huge difference in your application quality. How to prepare for a job interview at Denali Therapeutics Inc. ✨ Showcase Your Technical Know-How In biotechnology, it's crucial to demonstrate a strong grasp of relevant techniques and tools—so be prepared to discuss the lab methods you've used or any specific projects you’ve been part of. Bring along any data or results that highlight your contributions; we want to s … y data or results that highlight your contributions; we want to see how you can apply science to real-world problems! ✨ Brush Up on Your Problem-Solving Skills Biotech interviews often include hypothetical scenarios where you might have to troubleshoot a research problem. Practice articulating your thought process as you navigate these challenges
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.7 %���� 1 0 obj >/Metadata 185 0 R/ViewerPreferences 186 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�� �r�F�]U��y$�D�ܸT���z�v��R����X���뷻g� ejUI$�>���O]^U6����ysy]Uq2)�z� �_>,���s ����k��g�>?{ �����K��.�>�8'�� {��]v0�FV��u�靔�w��e����k�V�27���9�#-�����n�qĽ����~ �����}�!�Ǭ'�������� �sQ��k�;�u�p]���p��ޖ�m�p�{�k��1��T���Q%�62��6 ^y���W?�:�ա�^ B�t���#u9������� �x���t�y��Yޜv�u.��"��Л�8 �ư�s�4���*�|���
Denali Therapeutics Inc. – Plans of Reorganization, Merger, Acquisition or Similar – BamSEC Toggle navigation Features New Screening Tools Document Search Table Tools Collaboration Organization Other Pricing Contact Log In Free Trial BamSEC and AlphaSense Join Forces Learn More Denali Therapeutics Inc. – Plans of Reorganization, Merger, Acquisition or Similar Watch NASDAQ: DNLI Share price (6/26/26): $25.57 Market cap (6/26/26): $4.058 billion Warning: Large portions of this site require JavaScript enabled in order to function properly. P
Denali Therapeutics: rising to the challenge of brain disease | Baillie Gifford Ireland Professional investor Change Client Login Contact us You are viewing this site as a Professional Investor in accordance with MiFID legislation in Ireland. You can change this at any time. If you confirm these details are correct, we'll save this information. The details you select will be saved for 90 days. 01. Your location Ireland Change Select region Europe, Middle East & Africa Americas Asia Pacific Select country Ireland Austria Belgium Denmark Finland France Germany Guernsey Iceland Israel Italy J … unified social credit code of 91310000MA1FL6KQ30. BGIMS is a registered Private Fund Manager with the Asset Management Association of China (‘AMAC’) and manages private security investment fund in the PRC, with a registration code of P1071226. Baillie Gifford Overseas Investment Fund Management (Shanghai) Limited 柏基海外投资基金管理(上海)有限公司(‘BGQS’) is a wholly owned subsidiary of BGIMS incorporated in Shanghai as a limited liability company with its unified social credit code of 91310 … unified social credit code of 91310000MA1FL7JFXQ. BGQS is a registered Private Fund Manager with AMAC with a registration code of P1071708. BGQS has been approved by Shanghai Municipal Financial Regulatory Bureau for the Qualified Domestic Limited Partners (QDLP) Pilot Program, under which it may raise funds from PRC investors for making overseas investments. Hong Kong Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited a … ment Management (Europe) Limited (‘BGE’) relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec. Israel Baillie Gifford Overseas is not licensed under Israel’s Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755–1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients liste … age’s UK shareholder base. Before joining in 2019, she spent over a decade as a fund manager with a focus on managing European equity portfolios for a global client base. With a background in analysing companies and communicating investment ideas, Claire is also responsible for creating engaging content that makes the Scottish Mortgage portfolio
Statutory Price Disclosures - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Statutory Price Disclosures Wholesale Acquisition Cost Information for Colorado Prescribers Wholesale Acquisition Cost Information for Connecticut Prescribing Practitioners and Pharmacists Patients About Us Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Ther
Sanofi inks research deal with Denali in neurological, inflammatory diseases | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life … hat target the signaling protein RIPK1 in the TNF receptor pathway. Sanofi will fund all Phase 1b and Phase 2 clinical costs for all indications except Alzheimer's disease, while any Phase 3 investment will be 30% funded by Denali. Shares in Denali jumped up 10% upon market open Thursday. Dive Insight: Denali started 2018 with one research agreement with Takeda and is now ending the year with another big pharma collaboration. The Takeda deal, announced in January, paid $150 m … 2 testing for MS, ALS and any other neurological indications, while Denali will fund Alzheimer's Phase 1 testing. DNL758 is expected to begin clinical trials next year in rheumatoid arthritis and psoriasis For both drug candidates, Sanofi and Denali agreed to a 70-30 split on Phase 3 trial costs. Milestone payments are divided between $600 million for clinical and regulatory achievements in central nervous system products and $495 million for clinical, regulatory and commerci
Denali Therapeutics Job Openings & Careers | Justia Legal Jobs Post a Job Job Openings Post a Job AI Career Tools Legal Career Coach Cover Letter Generator Resume Review Interview Preparation Career Resources Newsletter Help Center in Find Jobs Justia Legal Jobs Denali Therapeutics Denali Therapeutics denalitherapeutics.com Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. Corporate Counsel, Employment & Privacy Full Time South San Francisco, CA $226,000 - $278,000 $226,000 - $278,000 Added Jun 12, 2026 Attorney
Tenvie Therapeutics, a Denali spinout, raises $200M as neuro company resets Skip to Main Content Manage alerts for this article Email this article Share this article Donald Trump Eli Lilly Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series &a … story subscribe to STAT+. Subscribe Log In biotechnology , neuroscience , STAT+ Submit a correction request Reprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “ The Readout Loud .” You can reach Allison on Signal at AllisonDeAngelis.01. Newsletter Your morning rundown of the science, politics, and money driving biotech to
Portfolio - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact Our Portfolio We build disruptive companies. Meet them. Read what our entrepeneurs are saying about ARCH. Agios Pharmaceuticals --> “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress. ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scie … htful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scango … htful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scango
Denali: defeating the blood-brain barrier | Scottish Mortgage About Us How To Invest FAQs Email Sign Up Home Insights Denali: Defeating the Blood-brain Barrier June 2024 Article Denali: Can Drug Treatments Defeat the Blood-brain Barrier? Claire Shaw – Portfolio Director Denali is engineering drugs to cross the blood-brain barrier to treat Alzheimer’s and other neurodegenerative diseases It uses transferrin receptors to bypass the blood-brain barrier's security measures If successful, it could have a wide-reaching impact on patients and investors As with any investment, your capital is at risk. … age’s UK shareholder base. Before joining in 2019, she spent over a decade as a fund manager with a focus on managing European equity portfolios for a global client base. With a background in analysing companies and communicating investment ideas, Claire is also responsible for creating engaging content that makes the Scottish Mortgage portfolio accessible to all its shareholders. Beyond that, she works closely with the managers, meeting with portfolio companies and conductin … ority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. BGA and BGAS are wholly owned subsidiaries of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Scottish Mortgage Investment Trust PLC (the “Company”) is an alternative investment fund for the purpose of Directive 2011/61/EU (the “AIFM Directive”). Baillie Gifford & … IFM Directive”). Baillie Gifford & Co Limited is the alternative investment fund manager (“AIFM”) of the Company and has been authorised for marketing to Professional Investors in this jurisdiction. This communication is made available by Baillie Gifford Investment Management (Europe) Limited (“BGE”), which has been engaged by the AIFM to carry out promotional activities relating to the Company. BGE is authorised by the Central Bank of Ireland as an AIFM under the AIFM Re … meaning of Luxembourg act by the act of 12 July 2013 on alternative investment fund managers (the AIFM Act). This communication does not constitute an offer, an invitation or a solicitation for any investment or subscription for the units/shares/interests of the Trust by retail investors in Luxembourg. Any person who is in possession of this doc
%PDF-1.6 %���� 7 0 obj > endobj 75 0 obj >/Filter/FlateDecode/ID[ ]/Index[7 186]/Info 6 0 R/Length 278/Prev 404683/Root 8 0 R/Size 193/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"l@$�a)�Drv�H&�^f��[�H� `q}�6D23��'�H��`���H� Rh.�4���:GAl=W�� " k@�� 0�/D�، � $}/a`��4p�00���$5Iι44�?s�G�%�1 endstream endobj startxref 0 %%EOF 192 0 obj >stream h�b``pb``�����&%̀ �����Y� �3�30ؿq�(��-��k�� x~�s�!�h ���eŚ�H3 �iaI[# �ls�7+�)� �/ V-Sv��,-�$����ش�B | �v�9A endstream endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj >stream h��Zio�H��+������}y��q'��$��� ���h�Ӓ�!)/�~�-��� … -06T13:33:21-05:00 2017-01-06T13:33:21-05:00 Mac OS X 10.11.6 Quartz PDFContext application/pdf uuid:a17b80ff-4fc8-1543-a8c8-be1238b74cdc uuid:1391715c-5eea-de43-ba36-ff709594c44f endstream endobj 2 0 obj >stream h�2U0P���w�/�+Q0���L)�����T��$�����w � endstream endobj 3 0 obj >stream h�2S0P���w.JM,���sI,I�p�220470403�044������OA�26662�50U70P��(�O)MN-��MLV�V�P04�34�3S,M,*�Rpqs��+I�(Ѵ�09) endstream endobj 4 0 obj >/Filter/FlateDecode/ID[ ]/Info 6 0 R/Length 39/R
Denali Therapeutics - F-Prime Capital Skip to content F-Prime Capital People Portfolio Impact Search Home People Portfolio Life Sciences Technology Healthtech + Services Crypto Impact About Jobs Fintech Index Denali Therapeutics NASDAQ: DNLI Developing therapies for neurodegenerative diseases through rigorous research. Developing therapies for neurodegenerative diseases through rigorous research. Investment Team Stephen Knight, MD Stacie Weninger, PhD Sector Life Sciences Category Therapeutics Location San Francisco, CA Initial Investment Created 2015 Denali Therapeutics (NASDAQ:DNLI) is dedic
Denali Therapeutics Inc Company Profile - Denali Therapeutics Inc Overview - GlobalData Visit Corporate Site Sign in Search Menu Sign In Who We Are Who We Are Your powerful market insights platform. Book a demo Mission & Values Clients Media People Why GlobalData Resource Center CSR Partners Careers History Investors Industries We Cover Industries We Cover Your curated industry news round-up. Subscribe now Aerospace, Defense & Security Agribusiness Apparel Automotive Banking & Payments Construction Consumer Foodservice Healthcare Insurance Medical Devices Mining Oil & Gas Packa … r Event Description 2025 Regulatory Approval In January, the company received a grant breakthrough therapy designation from the US Food and Drug Administration for tividenofusp alfa (DNL310) to treat individuals with Hunter syndrome (MPS II). 2022 Official Trials/Tests In May, the company and Biogen Inc announced the initiation of phase 2b study of LRRK2 inhibitor in Parkinson’s disease. 2022 Others In May, the company and Sanofi commenced dosing in a Phase 2 study, HI … wanted Did not find what I wanted (Let us Contact you) It's too expensive Other Submit Popular Company Profiles: Abbott Laboratories ; Pfizer Inc ; Medtronic Plc ; Shell plc ; BP Plc ×
Ryan Watts, Ph.D. - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers 07/16/2025 Share Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadership
Marc Tessier-Lavigne - The AI Conference ← Back to All Speakers See all sessions and speakers at The AI Conference . Marc Tessier-Lavigne Co-founder, Chairman & CEO Xaira Panel Title: AI in Healthcare and Biotech Panel Summary: AI isn’t just speeding up science—it’s transforming care. Experts from Xaira , Pfizer , and Menlo Ventures discuss how AI is reshaping everything from drug discovery to patient outcomes and personalized care. SUBSCRIBE About | Marc Tessier-Lavigne Marc Tessier-Lavigne is Co-founder, Chairman & CEO of Xaira Therapeutics . Previously, he held executive roles at G … recipient of numerous scientific awards, including the 2020 Gruber Neuroscience Prize , and has been elected to the US National Academy of Sciences and the US National Academy of Medicine . He is also an Officer of the Order of Canada . Dr. Tessier-Lavigne is a Co-founder and Director of Denali Therapeutics , and previously co-founded Renovis . He has served on the boards of Regeneron , Pfizer , Agios , and Juno .
Meet the Next President | STANFORD magazine Log in --> Latest Features Essays Advice Collections University Ave. Resolutions Love Students Stanford In Space After the Farm Recent Grads Work The Stanfords Books Magazine Current Issue Past Issues Audio Articles Online Exclusives Class Notes Contact Search Menu Close Latest Features Essays Advice Collections University Ave. Resolutions Love Students Stanford In Space After the Farm Recent Grads Work The Stanfords Books Magazine Current Issue Past Issues Online Exclusives Past Issues Audio Articles Class Notes Contact Close Hello, what can we help … ecent Grads Work The Stanfords Books Get in touch Contact Letters to the Editor Submit an Obituary Advertise FAQs Accessibility Privacy Policy Terms of Use Code of Conduct Stanford Home Maps & Directions Search Stanford Emergency Info Terms of Use Privacy Copyright Trademarks Non-Discrimination Accessibility Terms of Use Privacy Copyright Trademarks Non-Discrimination Accessibility © Stanford University. Stanford, California 94305.
About Us - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Patients Careers Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadership Investor
Joe Lewcock, Ph.D. - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers 07/16/2025 Share Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadershi
STEM Outreach - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers About Us Home Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadership Invest
Alexander Schuth, M.D. - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers 07/16/2025 Share Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leade
Internships - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers About Us Home Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadership Investor
Dana Andersen, Ph.D. - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers 07/16/2025 Share Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leaders
Careers - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers About Us Home Your browser does not support the video tag. Science TransportVehicle™ Platform Publications Partnerships & Collaborations Product & Pipeline Product Pipeline Patients Our Commitment Advocacy Grants & Sponsorships Therapeutic Areas Clinical Studies Early Access Program Medical Professionals Get in Touch Clinical Studies Recent Publications Grants & Sponsorships Early Access Program About Us About Us Leadership Investors &a
Science - Denali Therapeutics Investors & News Contact Us Science Product & Pipeline Patients Medical Professionals About Us Careers Partnerships & Collaborations Contact Us Collaborations are core to Denali’s strategy to develop and commercialize our portfolio. We partner with leading biopharmaceutical companies, academic institutions, foundations and enabling technology companies to advance treatments for neurodegenerative diseases, lysosomal storage disorders and other serious diseases. Contact Us Product & Pipeline Patients Your browser does not support the video tag. Sci